Risks of novel oral prostate cancer therapies and pre-existing conditions
PHILADELPHIA -A new large population-based study from the Sidney Kimmel Cancer Center—Jefferson Health shows that novel oral androgen signaling inhibitor therapies are associated with an increased risk of death in patients ...
Aug 13, 2019
0
0